Learn more about Peter Attia’s digital program
The straight dope on cholesterol – Part VIII
In this post we’ll double-click on a paper covering cholesterol and heart disease risk factors.
#63 – AMA #7: Exercise framework, deadlifting, lower back pain, blood pressure, nootropics, CGM, and more
“The single greatest risk to my longevity is my lower back.” —Peter Attia
#102 – Michael Osterholm, Ph.D.: COVID-19—Lessons learned, challenges ahead, and reasons for optimism and concern
“We’re seeing an increased number of severe illnesses and deaths in people between the ages of 25 and 50…and the risk factor appears to be obesity.” —Michael Osterholm
#123 – Joan Mannick, M.D. & Nir Barzilai, M.D.: Rapamycin and metformin—longevity, immune enhancement, and COVID-19
“I think what the mTOR inhibitors are doing is not stopping people from getting infected [with a virus], but if you get infected, there’s a better immune response and your symptoms will be milder.” — Joan Mannick
#164 – Amanda Smith, M.D.: Diagnosing, preventing, and treating Alzheimer’s disease, and what we can all learn from patients with dementia
“At the end of the day, it really has to do with how people see themselves, how people interact with the world, what kind of relationships they have, how able they are to let go of things that they’ve lost and how able they are to focus on the positive.” —Amanda Smith
#175 – Matt Kaeberlein, Ph.D.: The biology of aging, rapamycin, and other interventions that target the aging process
“I don’t think I will ever understand aging fully. And I don’t think the field will. … But I also believe that we don’t have to understand it fully to be able to have an impact on the biology of aging through interventions.” —Matt Kaeberlein
About TAME: A Metformin Anti-Aging Clinical Trial with Nir Barzilai, M.D.
This video clip is from episode #204 – Centenarians, metformin, and longevity with Nir Barzilai, M.D., originally released on April…
#173 – AMA #26: Continuous glucose monitors, zone 2 training, and a framework for interventions
“Zone two is a metabolic state. It’s not determined by speed. It’s determined by which energy system you’re requiring and what the equilibrium is.” —Peter Attia
#238 – AMA #43: Understanding apoB, LDL-C, Lp(a), and insulin as risk factors for cardiovascular disease
“ApoB is a necessary, though not sufficient, factor in the development of ASCVD which means the more you lower it, the more you lower risk. Full stop.” —Peter Attia
Continuous glucose monitoring to improve health in non-diabetics
Individualizing blood glucose control and its benefits